Literature DB >> 12433741

New BMJ policy on economic evaluations.

Richard Smith.   

Abstract

Mesh：

Year:  2002        PMID： 12433741      PMCID： PMC1124620          DOI： 10.1136/bmj.325.7373.1124

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.

Authors:  D Moher; K F Schulz; D G Altman
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

2.  Quality of economic evaluations in health care.

Authors:  Tom Jefferson; Vittorio Demicheli
Journal:  BMJ       Date:  2002-02-09

3.  Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.

Authors:  M F Drummond; T O Jefferson
Journal:  BMJ       Date:  1996-08-03

4.  New horizons in medical ethics. Priorities in medicine.

Authors:  P Rhodes; C Ogg; D Irvine
Journal:  Br Med J       Date:  1973-06-16

5.  Multicentre aneurysm screening study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial.

Authors: 
Journal:  BMJ       Date:  2002-11-16

6.  Content and quality of 2000 controlled trials in schizophrenia over 50 years.

Authors:  B Thornley; C Adams
Journal:  BMJ       Date:  1998-10-31

7.  The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial.

Authors:  H A Ashton; M J Buxton; N E Day; L G Kim; T M Marteau; R A P Scott; S G Thompson; N M Walker
Journal:  Lancet       Date:  2002-11-16       Impact factor: 79.321
  7 in total
  7 in total

1.  New BMJ policy on economic evaluations. Response of NHS Economic Evaluation Database Research Team.

Authors:  Dawn Craig; John Nixon; Nigel Armstrong; Julie Glanville; Jos Kleijnen; Michael Drummond
Journal:  BMJ       Date:  2003-02-22

Review 2.  Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysis.

Authors:  Dan Greenberg; Allison B Rosen; Natalia V Olchanski; Patricia W Stone; John Nadai; Peter J Neumann
Journal:  BMJ       Date:  2004-04-20

3.  Reporting pharmacoeconomic evaluations.

Authors:  C I Carswell; J A Paladino
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Publication patterns of cancer cost-effectiveness studies presented at major conferences.

Authors:  K K Chan; E Siu; L Mozessohn; M C Cheung
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

Review 5.  Can the Spanish care system assume the new costs of medications against cancer?

Authors:  Carlos Camps; Cristina Caballero; Rafael Sirera; Ana Blasco; Diego Cayuela; Mireia Gil; Xavier Badía
Journal:  Clin Transl Oncol       Date:  2008-02       Impact factor: 3.405

Review 6.  Shared care across the interface between primary and specialty care in management of long term conditions.

Authors:  Susan M Smith; Gráinne Cousins; Barbara Clyne; Shane Allwright; Tom O'Dowd
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

7.  Peer support in type 2 diabetes: a randomised controlled trial in primary care with parallel economic and qualitative analyses: pilot study and protocol.

Authors:  Gillian M Paul; Susan M Smith; David L Whitford; Eamon O'Shea; Fergus O'Kelly; Tom O'Dowd
Journal:  BMC Fam Pract       Date:  2007-07-31       Impact factor: 2.497
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.